导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.34% | 2500/4773 |
| 近一周 | -1.50% | 2239/5465 |
| 近一月 | -3.21% | 2271/5421 |
| 近一季 | -5.68% | 2152/5231 |
| 近半年 | -1.96% | 1962/4920 |
| 近一年 | 1.74% | 2423/4394 |
| 近两年 | 46.11% | 1630/2954 |
| 近三年 | 27.39% | 1195/2253 |
| 成立以来 | 99.91% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.34% 3146/4961 |
11.79% 2295/5312 |
- - |
- - |
| 2025 | 18.98% 2264/4813 |
-1.02% 2540/3635 |
1.81% 2123/4076 |
18.01% 2368/4524 |
0.05% 2256/4813 |
| 2024 | 13.99% 1083/3463 |
2.11% 815/2808 |
-1.73% 1102/3014 |
15.84% 1613/3129 |
-1.93% 1890/3463 |
| 2023 | -10.30% 1284/2656 |
2.76% 1304/2280 |
-4.60% 1215/2385 |
-3.35% 903/2515 |
-5.34% 1323/2655 |
| 2022 | -16.89% 528/2207 |
-13.61% 796/1919 |
7.23% 505/2016 |
-11.78% 579/2113 |
1.68% 1179/2208 |
| 2021 | 5.42% 546/1822 |
-2.37% 630/1255 |
8.58% 612/1330 |
-2.94% 604/1466 |
2.46% 589/1822 |
| 2020 | 39.98% 320/1250 |
-6.50% 490/1028 |
16.69% 421/1067 |
13.45% 319/1164 |
13.09% 396/1184 |
| 2019 | 37.91% 325/1092 |
25.24% 476/739 |
-0.34% 246/788 |
2.48% 297/850 |
7.82% 392/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 华泰MSCI中国A股联接C VS. 长安沪深300非周期A(740101) |